Stockscreener 앱 받기
12.60
2.33%
-0.30
시간 외 거래:
12.50
-0.10
-0.79%
전일 마감가:
$12.90
열려 있는:
$13.03
하루 거래량:
23,983
Relative Volume:
0.29
시가총액:
$112.99M
수익:
-
순이익/손실:
$-40.62M
주가수익비율:
-0.6492
EPS:
-19.4076
순현금흐름:
$-35.63M
1주 성능:
-8.60%
1개월 성능:
-7.15%
6개월 성능:
-47.61%
1년 성능:
+17.21%
1일 변동 폭
$12.48
$13.46
1주일 범위
$12.48
$14.34
52주 변동 폭
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
12.60 | 133.71M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - Kalkine
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences (PMN): Wellington group discloses 7.77% ownership stake - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - The Manila Times
ProMIS Neurosciences (PMN) Shares Drop 8% as Stock Tests Key Support LevelETF AUM Growth - vinanet.vn
ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN - MarketBeat
Alzheimer Agent PMN310 Shows No ARIA-E in Six-Month Interim Analysis of Phase 1b AD Trial - neurologylive.com
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker D - GuruFocus
Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada
ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus
ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):